Results 31 to 40 of about 2,440 (155)

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator

Human Vaccines & Immunotherapeutics, 2022
The current scenario of typhoid fever warrants early prevention with typhoid conjugate vaccines in susceptible populations to provide lifelong protection.
Subhash Thuluva, Vikram Paradkar, Ramesh Matur, Kishore Turaga, Subba Reddy GV   +4 more
doaj   +1 more source

One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine

International Journal of Infectious Diseases, 2020
Introduction: World Health Organization estimates the annual global incidence of typhoid fever at 11-21 million cases and approximately 128 000 to 161 000 deaths.
Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, Hartono Gunardi, Rini Sekartini, Hindra Irawan Satari, Sri Rezeki Hadinegoro, Angga Wirahmadi, Mita Puspita, Rini Mulia Sari, Jae Seung Yang, Arijit Sil, Sushant Sahastrabuddhe, Novilia Sjafri Bachtiar   +12 more
doaj   +1 more source

A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report

BMC Pediatrics, 2020
Background Typhoid fever caused by Salmonella enteric serovar Typhi (S. Typhi) is a common cause of morbidity in the world. In 2017, 14.3 million cases of Typhoid and paratyphoid fever occurred globally.
Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, Hartono Gunardi, Rini Sekartini, Hindra Irawan Satari, Sri Rezeki Hadinegoro, Angga Wirahmadi, Mita Puspita, Rini Mulia Sari, Jae Seung Yang, Arijit Sil, Sushant Sahastrabuddhe, Novilia Sjafri Bachtiar   +12 more
doaj   +1 more source

The Design and Analysis of Seroefficacy Studies for Typhoid Conjugate Vaccines [PDF]

Clinical Infectious Diseases, 2019
AbstractBackgroundDemonstrating the efficacy of new Vi-conjugate typhoid vaccines is challenging, due to the cost of field trials requiring tens of thousands of participants. New trial designs that use serologically defined typhoid infections (seroefficacy trials) rather than blood culture positivity as a study endpoint may be useful to assess efficacy
Liu, X, Pitzer, V, Pollard, A, Voysey, M
openaire   +3 more sources

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial

The Lancet Global Health, 2021
Summary: Background: Typhoid fever is a major public health problem in low-resource settings. Vaccination can help curb the disease and might reduce transmission.
Mila Shakya, MPH, Merryn Voysey, DPhil, Katherine Theiss-Nyland, PhD, Rachel Colin-Jones, MA, Dikshya Pant, FCPS, Anup Adhikari, MA, Susan Tonks, BSc, Yama F Mujadidi, MSc, Peter O’Reilly, MBBCh, Olga Mazur, MSc, Sarah Kelly, MSc, Xinxue Liu, PhD, Archana Maharjan, MA, Ashata Dahal, MPH, Naheeda Haque, PharmD, Anisha Pradhan, BSc, Suchita Shrestha, MPH, Manij Joshi, BPharm, Nicola Smith, MBBCh, Jennifer Hill, PhD, Jenny Clarke, PhD, Lisa Stockdale, PhD, Elizabeth Jones, BMedSc, Timothy Lubinda, MSc, Binod Bajracharya, MD, Sabina Dongol, DPhil, Abhilasha Karkey, DPhil, Stephen Baker, ProfPhD, Gordan Dougan, ProfPhD, Virginia E Pitzer, ScD, Kathleen M Neuzil, ProfMD, Shrijana Shrestha, ProfMD, Buddha Basnyat, ProfFRCPE, Andrew J Pollard, ProfFMedSci   +33 more
doaj   +1 more source

Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study

EClinicalMedicine, 2020
Background: Typhoid causes significant mortality among young children in resource-limited settings. Conjugate typhoid vaccines could significantly reduce typhoid-related child deaths, but only one WHO-prequalified typhoid conjugate vaccine exists for ...
Maria Rosario Capeding, Arijit Sil, Birkneh Tilahun Tadesse, Tarun Saluja, Samuel Teshome, Edison Alberto, Deok Ryun Kim, Eun Lyeong Park, Ju Yeon Park, Jae Seung Yang, Suchada Chinaworapong, Jiwook Park, Sue-Kyoung Jo, Yun Chon, Seon-Young Yang, Ji Hwa Ryu, Inho Cheong, Kyu-Young Shim, Yoonyeong Lee, Hun Kim, Julia A. Lynch, Jerome H. Kim, Jean-Louis Excler, T. Anh Wartel, Sushant Sahastrabuddhe   +24 more
doaj   +1 more source

A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination

Microorganisms, 2021
Vi-polysaccharide conjugate vaccines are efficacious against typhoid fever in children living in endemic settings, their recent deployment is a promising step in the control of typhoid fever.
Elizabeth Jones, Celina Jin, Lisa Stockdale, Christina Dold, Andrew J. Pollard, Jennifer Hill   +5 more
doaj   +1 more source

Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children [PDF]

Lancet, The
Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA, TyVAC team.   +22 more
exaly   +2 more sources

A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children [PDF]

Journal of Clinical and Diagnostic Research, 2015
Background and Objectives: Owing to the limitations of the conventional polysaccharide vaccines, global efforts have been made to develop conjugated polysaccharide vaccines for typhoid. Duration of immune response induced by these vaccines is critical
Balaji Chinnasami, Kanimozhi Sadasivam, Aravindhan Vivekanandhan, Prema Arunachalam, Sekar Pasupathy   +4 more
doaj   +1 more source

Early Insights From Clinical Trials of Typhoid Conjugate Vaccine [PDF]

Clinical Infectious Diseases, 2020
Abstract Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions.
Kathleen M. Neuzil, Buddha Basnyat, John D. Clemens, Melita A. Gordon, Priyanka Patel, Andrew J. Pollard, Mila Shakya, Firdausi Qadri   +7 more
openaire   +3 more sources